肝癌病人PD-ECGF血浆水平的检测

Detection of PD-ECGF Plasma Level in Patients with Hepatocellular Carcinoma

目的 检测肝细胞癌 (HCC)病人血浆中血小板衍化内皮细胞生长因子 (PD ECGF)水平 ,探讨其与HCC临床病理特征的关系。方法 选取在我所行手术切除并经病理证实的HCC病人 6 1例。以 10例正常人和15例肝炎肝硬化病人作为对照。血浆PD ECGF水平检测用酶联免疫吸附法 (ELISA)。结果 HCC病人血浆中PD ECGF水平明显高于正常人和肝炎肝硬化病人 (P <0 .0 5 ) ,而正常人和肝炎肝硬化病人的血浆水平比较差异无显著性 (P >0 .0 5 )。高TNM分期和伴有门静脉癌栓的HCC病人PD ECGF血浆水平分别高于低TNM分期和无门静脉癌栓者 ,差异有显著性 (P <0 .0 5 )。PD ECGF血浆水平在其他临床病理指标对应的肝癌病人之间比较无明显差异 (P >0 .0 5 )。结论 肝癌病人的血浆PD

Purpose: To detect the plasma level of platelet-derived endothelial cell growth factor(PD-ECGF) in patients with hepatocellular carcinoma (HCC) and explore its relation to the clinicopathological futures of HCC. Methods: 61 cases of patients with HCC were enrolled in this study, whose HCC nodules were removed from March 1998 to June 1999 in our institute. Enzyme linked immunosorbent assay(ELISA) was used to detect the plasma level of PD-ECGF in these patients with HCC and 10 normal individuals as well as 15 patients with hepatitis and liver cirrhosis. Results: The plasma PD-ECGF concentration in 61 patients with HCC[(3.02 ± 1.55) ng/ml] was highest among three groups and was significantly higher than in those normal individuals [(1.98 ± 0.92) ng/ml] and in patients with hepatitis and liver cirrhoss[(2.28 ± 1.04) ng/ml] respectively(P 0.05). Conclusions: Plasma PD-ECGF increases in patients with HCC and is related to the formation of portal vein tumor thrombus.